Рет қаралды 567
Fredrik Brag, CEO and founder of Median, provides additional insight on our two latest company’s announcements: the FDA 513(g) regulatory submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device and the design completion of iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance (interview in French).